fr

Inscription
Tout investissement comporte des risques et ne convient pas à tout le monde.

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Accueil・Liste d'Actions・Cytokinetics Inc
Search

Cytokinetics Inc

Fermé

Secteur Soins de santé

54.16 -3.03

Achat Fort

Actualisation du prix 6 sept. 2024, 19:59 UTC

AcheterVendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

53.97

Max

54.82

Chiffres clés

By Trading Economics

Revenu

-7.7M

-143M

Ventes

24M

25M

BPA

0.08

Marge bénéficiaire

-570.761

Employés

423

EBITDA

-622K

-117M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+51.32 upside

Dividendes

By Dow Jones

Prochains Résultats

31 oct. 2024

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-58M

5.9B

Ouverture précédente

57.19

Clôture précédente

54.16

Sentiment de l'Actualité

By Acuity

80%

20%

324 / 365 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

53.16 / 55.02 Support & Résistance

Cytokinetics Inc Graphique

Actualités Associées

5 juin 2024, 15:26 UTC

Acquisitions, Fusions, Rachats

Cytokinetics CEO Says Board Would Have Backed Actionable Buyout

DJ

Lire

11 janv. 2024, 17:47 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

Cytokinetics Shares Slide as Novartis Reportedly Shies Away From Deal

DJ

Lire

8 janv. 2024, 18:28 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

Cytokinetics Shares Jump 16% After WSJ Report of Novartis Deal

DJ

Lire

5 juin 2024, 14:14 UTC

Acquisitions, Fusions, Rachats

Cytokinetics: Board, Management Would Never Stand in Way of Value-Maximizing Transaction >CYTK

DJ

Lire

5 juin 2024, 14:14 UTC

Acquisitions, Fusions, Rachats

Cytokinetics CEO: Board Would Have Supported Actionable Proposal in Best Interests of Shareholders >CYTK

DJ

Lire

5 juin 2024, 14:14 UTC

Acquisitions, Fusions, Rachats

WSJ Reported in January That Novartis Backed Away From Pursuit of Cytokinetics >CYTK

DJ

Lire

5 juin 2024, 14:14 UTC

Acquisitions, Fusions, Rachats

Cytokinetics CEO: Other Party Didn't Move Forward With Acquisition >CYTK

DJ

Lire

5 juin 2024, 14:14 UTC

Acquisitions, Fusions, Rachats

Cytokinetics CEO: Board Was Supportive of Moving Forward on Deal on Terms Company Believed Would Be Mutually Acceptable >CYTK

DJ

Lire

5 juin 2024, 14:14 UTC

Acquisitions, Fusions, Rachats

Cytokinetics CEO: Previously Held Good-Faith Talks With Another Party on Acquisition of Company >CYTK

DJ

Lire

11 janv. 2024, 17:47 UTC

Actualités
Acquisitions, Fusions, Rachats

Novartis Pursuit of Cytokinetics Cools -- Update

DJ

Lire

11 janv. 2024, 17:19 UTC

Actualités
Acquisitions, Fusions, Rachats

Novartis Pursuit of Cytokinetics Cools -- WSJ

DJ

Lire

11 janv. 2024, 17:19 UTC

Acquisitions, Fusions, Rachats

Swiss Drug Maker Had Been Expected to Clinch Deal for Heart-Drug Developer as Soon as This Week -- WSJ

DJ

Lire

11 janv. 2024, 17:19 UTC

Acquisitions, Fusions, Rachats

Novartis Pursuit of Cytokinetics Cools, Sources Say -- WSJ

DJ

Lire

8 janv. 2024, 21:42 UTC

Acquisitions, Fusions, Rachats

Cytokinetics Has Clawed Back 105% Over Seven Days. Now It Could Score A Buyout. -- IBD

DJ

Lire

8 janv. 2024, 19:13 UTC

Acquisitions, Fusions, Rachats

Cytokinetics Rockets 14% As Novartis Reportedly Nears A Buyout Deal -- IBD

DJ

Lire

8 janv. 2024, 18:25 UTC

Acquisitions, Fusions, Rachats

Novartis, Cytokinetics Near Merger: Report -- MarketWatch

DJ

Lire

8 janv. 2024, 18:14 UTC

Actualités
Acquisitions, Fusions, Rachats

Novartis in Advanced Talks to Buy Cytokinetics -- Update

DJ

Lire

8 janv. 2024, 17:56 UTC

Actualités
Acquisitions, Fusions, Rachats

Novartis in Advanced Talks to Buy Cytokinetics -- WSJ

DJ

Lire

8 janv. 2024, 17:56 UTC

Acquisitions, Fusions, Rachats

Deal Could Be Reached as Soon as This Week, Sources Say -- WSJ

DJ

Lire

8 janv. 2024, 17:56 UTC

Acquisitions, Fusions, Rachats

Novartis in Advanced Talks to Buy Cytokinetics, Sources Say -- WSJ

DJ

Lire

31 oct. 2023, 17:49 UTC

Market Talk
Acquisitions, Fusions, Rachats

Cytokinetics May Have Some Tire Kickers -- Market Talk

DJ

Lire

Comparaison

Variation de prix

Cytokinetics Inc prévision

Objectif de Prix

By TipRanks

51.32% hausse

Prévisions sur 12 Mois

Moyen 81.85 USD  51.32%

Haut 107 USD

Bas 60 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

14 ratings

11

Achat

3

Maintien

0

Vente

Basé sur 14 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

53.16 / 55.02Support & Résistance

Court Terme

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Moyen Terme

Bearish Evidence

Recent bearish events outweigh bullish events.

Long Terme

Weak Bearish Evidence

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

324 / 365Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Cytokinetics Inc

Cytokinetics, Incorporated is a late-stage biopharmaceutical company that is focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The Company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The Company is conducting METEORIC-HF, a second Phase III clinical trial of omecamtiv mecarbil. It is also developing aficamten, a cardiac myosin inhibitor, for the potential treatment of HCM. The Company also conducts research and development on novel treatments for disorders involving muscle function beyond muscle contractility. The Company’s lead drug candidates in clinical development are omecamtiv mecarbil, a cardiac myosin activator; CK-136, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.

Autres valeurs du secteur

LLY

Eli Lilly and Co.

902.74

↓-0.9%

UNH

UnitedHealth Group Inc

596.8

↑ +0.31%

NVO

Novo Nordisk A-S

131.05

↑ +0.18%

JNJ

Johnson and Johnson

164.37

↓-0.29%

ABBV

AbbVie Inc

193.18

↑ +0.34%